This document provides a detailed stock report for Pmv Pharmaceuticals Inc (PMVP) as of June 3rd, 2022. The report summarizes the company's poor risk-adjusted returns, high volatility, and below median dividend returns compared to its peers. It also includes the stock's current price and market cap, analyst ratings and price targets for the stock, and comparative performance data versus industry and market benchmarks. The report recommends seeking advice from a licensed professional before making any investment decisions.

1. Page 1 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
PMVP:NSD (Pmv Pharmaceuticals Inc)
Others | NSD | Common Stock
Values as of 2nd Jun, 2022
Stock Target Advisor
Detailed Stock Report
Report Date: 3rd June, 2022
Last Close
USD 13.56
Change
+1.83(+15.60%)
Market Cap
USD 0
1 Yr Capital Gain
-59.65%
1 Yr Dividend Return
N/A
1 Yr Total
Return
-59.65%
Earning Growth (5 yr)
N/A
Average Target Price
27.50(+102.80% )
Average Analyst
Rating
Strong Buy
Fundamental
Analysis
N/A
Our view of the stock is Very Bearish with a score of 0 out of 10, where 0 is very bearish and 10 very bullish
What to like
There is nothing we particularly like
What to not like
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

2. Page 2 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
PMVP:NSD (Pmv Pharmaceuticals Inc)
Others | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 3rd June, 2022
Adjusted Closing Share Volume
Relative Returns Relative Performance (Total Returns)
Security Capital Gain Dividend Return Total Return
PMVP
Pmv Pharmaceuticals Inc
-58% 0 -58%
QQQ
Invesco QQQ Trust
-5.7% +0.4% -5.3%

3. Page 3 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Technical Indicators
Value Value
Beta N/A 52 Week High N/A
Short Ratio N/A 52 Week Low N/A
Shorted Shares N/A 200 Day Moving Average N/A
Shorted Shares Previous Month N/A 50 Day Moving Average N/A
Shares Held By Insiders N/A Short Percentage N/A
Shares Held by Institutions N/A Dividend Yield N/A

4. Page 4 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
PMVP:NSD (Pmv Pharmaceuticals Inc)
Others | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 3rd June, 2022
Market Performance
Market Performance vs. Industry / Classification (Others) Market Performance vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
YTD
Capital Gain -41.30% -13.6% 34% -16.4% 28%
Dividend Return N/A 1.5% N/A 1.0% N/A
Total Return -41.30% -13.2% 34% -16.0% 28%
Trailing 12 Months
Capital Gain -59.65% -12.4% 33% -19.2% 27%
Dividend Return N/A 3.0% N/A 2.3% N/A
Total Return -59.65% -11.9% 33% -17.1% 27%
Trailing 5 Years
Capital Gain N/A -3.9% N/A 8.1% N/A
Dividend Return N/A 11.6% N/A 11.0% N/A
Total Return N/A 3.5% N/A 18.3% N/A
Average Annual (5 Year Horizon)
Capital Gain -18.64% -1.0% 12% 2.6% 9%
Dividend Return N/A 0.6% N/A 1.8% N/A
Total Return -18.64% -0.9% 12% 4.5% 9%
Risk Return Profile
Volatility (Standard
Deviation)
24.54% 12.2% 29% 32.2% 63%
Risk Adjusted Return -75.95% N/A 5% 20.7% 4%
Market Capitalization N/A 0.05B N/A 0.42B N/A

5. Page 5 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Key Financial Ratios
Ratios vs. Industry / Classification (Computer Hardware) Ratios vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
Market Value
peratio N/A 16.0 N/A 16.7 N/A
pbratio N/A 1.7 N/A 1.6 N/A
pcfratio N/A 0.0 N/A -0.1 N/A
pfcfratio N/A 1.7 N/A 10.1 N/A
Management Effectiveness
retequity N/A 129.7% N/A 0.3% N/A
retinvcap N/A -1.5% N/A -0.6% N/A
retass N/A -42.2% N/A 0.1% N/A
debtequityratio N/A 1,219.5% N/A 31.6% N/A
Technical Ratios
yield N/A 1.8% N/A 2.6% N/A
sratio N/A 1.02 N/A 3.06 N/A
spercent N/A 130.0% N/A 3.0% N/A
beta N/A 1.06 N/A 1.10 N/A

6. Page 6 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
PMVP:NSD (Pmv Pharmaceuticals Inc)
Others | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 3rd June, 2022
Recent Analyst Ratings
Price Action Rating Action Analyst Rating Price date
Maintains Goldman Sachs Buy USD 43 » USD 25 2022-05-24
Upgraded by Oppenheimer Holdings
Market Perform »
Outperform
USD 30 2022-03-02
Reiterated by HC Wainwright Buy USD 62 2021-11-15
Upgrades Goldman Sachs Buy USD 35 » USD 43 2021-09-22
Initiated by Oppenheimer Holdings Market Perform 2021-08-19
Initiates Coverage On Guggenheim Securities Buy USD 56 2021-08-02
Initiated by HC Wainwright Buy USD 63 2021-07-29

7. Page 7 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
PMVP:NSD (Pmv Pharmaceuticals Inc)
Others | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 3rd June, 2022
Annual Financial (USD)
No record found.

8. Page 8 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
PMVP:NSD (Pmv Pharmaceuticals Inc)
Others | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 3rd June, 2022
Quarterly Financial (USD)
No record found.

9. Page 9 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
PMVP:NSD (Pmv Pharmaceuticals Inc)
Others | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 3rd June, 2022
Largest Industry Peers for Others
Symbol Company Name Price(Change) Market Cap
ACWI iShares MSCI ACWI ETF +1.84 (+2.0%) USD 17.91B
CGABL The Carlyle Group Inc. 4.625% .. -0.14 (-0.7%) USD 16.14B
CNXCV Concentrix Corporation N/A USD 4.91B
BUG Global X Cybersecurity ETF +1.03 (+3.9%) USD 1.19B
TCRX Tscan Therapeutics Inc +0.06 (+1.9%) USD 0.82B
AGCWW Altimeter Growth Corp N/A USD 0.74B
ERESW East Resources Acquisition Com.. +0.05 (+64.8%) USD 0.42B
FREEW FREEW -0.05 (-10.0%) USD 0.28B
NFIN Netfin Acquisition Corp N/A USD 0.26B
HERO Global X Video Games & Esports.. +0.61 (+2.7%) USD 0.26B
The Stock Target Advisor platform run millions of calculations every day on over 30,000 Canadian and American stocks, comparing and
ranking their financial and market performance against their sectors and exchange.
We represent the percentile ranking using the following grading system.
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%